Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients

AIDS

Volumn 24, Issue 13, 2010, Pages 2029-2039

  Diaz, Alba ^a   Alós, Llúcia ^a   León, Agathe ^a   Mozos, Anna ^a   Caballero, Miguel ^a   Martinez, Antonio ^a   Plana, Montserrat ^a   Gallart, Teresa ^a   Gil, Cristina ^a   Leal, Manuel ^b   Gatell, Jose M ^a   García, Felipe ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

collagen deposition; HIV infection; immune reconstitution

Indexed keywords

COLLAGEN; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; PRIORITY JOURNAL; RISK FACTOR; SENESCENCE; TONSIL; TREATMENT DURATION; VIRUS LOAD;

ADULT; AGING; CD4 LYMPHOCYTE COUNT; COLLAGEN; FEMALE; FIBROSIS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PALATINE TONSIL; RISK FACTORS; VIRAL LOAD;

EID: 77955421014     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833c3268     Document Type: Article

References (47)

1. Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:168-175.
2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133:35-39.
3. Smith C, Sabin CA, Lampe F, Kinloch-de-Loes S, Gumley H, Carroll A, et al. The potential for CD4 cell increases in HIV-positive individuals who control viremia with highly active antiretroviral therapy. AIDS 2003; 17:963-969.
4. R T-cell count. J Acquir Immune Defic Syndr 2004; 36:702-713.
5. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48:350-361.
6. R T cell recovery with antiretroviral therapy: more than the sum of the parts. Clin Infect Dis 2009; 48:362-364.
7. R cell count restoration despite successful antiretroviral treatment and the need to start highly active antiretroviral therapy early. Clin Infect Dis 2009; 48:795-797.
8. R cell count restoration in HIV-infected patients receiving long-term anti-retroviral treatment. Clin Infect Dis 2009; 48:787-794.
9. R T cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093-1097.
10. Alos L, Navarrete P, Morente V, Garcia F, Garrido M, Plana M, et al. Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence. Mod Pathol 2005; 18:127-136.
11. Navarrete P, Morente V, Garcia F, Alos L, Arnedo M, Plana M, et al. Predictors of tonsillar tissue HIV-1 viral burden at baseline and after 1 year of antiretroviral therapy. Antivir Ther 2003; 8:635-637.
12. Schacker TW, Nguyen PL, Martinez E, Reilly C, Gatell JM, Horban A, et al. Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis 2002; 186:1092-1097.
13. Garcia F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, et al. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple anti-retroviral therapy in very early stages: the Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study. J Acquir Immune Defic Syndr 2000; 25:26-35.
14. Martinez E, Arnedo M, Gil C, Caballero M, Alós L, García F, et al. Lymphoid tissue viral burden and duration of viral suppression in plasma. AIDS 2001; 15:1477-1482.
15. R cell response in HIV-1 infected patients receiving antiretroviral therapy. Clin Infect Dis 2000; 30:392-394.
16. Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van LJ, Lewis G, et al. Persistence of HIV-1 structural proteins and glyco-proteins in lymph nodes of patients under highly active anti-retroviral therapy. Proc Natl Acad Sci\USA 2005; 102:14807-14812.
17. Connick E, Mattila T, Folkvord JM, Schlichtemeier R, Meditz AL, Ray MG, et al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol 2007; 178:6975-6983.
18. Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007; 109:4272-4279.
19. Mozos A, Garrido M, Carreras J, Plana M, Diaz A, Alos L, et al. Redistribution of FOXP3-positive regulatory T cells from lym-phoid tissues to peripheral blood in HIV-infected patients. J Acquir Immune Defic Syndr 2007; 46:529-537.
20. R T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Semin Immunol 2008; 20:181-186.
21. Schacker TW, Nguyen PL, Beilman GJ, Wolinsky S, Larson M, Reilly C, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002; 110:1133-1139.
22. R T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006; 13:556-560.
23. Schacker TW, Reilly C, Beilman GJ, Taylor J, Skarda D, Krason D, et al. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS 2005; 19:2169-2171.
24. Estes J, Baker JV, Brenchley JM, Khoruts A, Barthold JL, Bantle A, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008; 198:456-464.
25. Nies-Kraske E, Schacker TW, Condoluci D, Orenstein J, Brench-ley J, Fox C, et al. Evaluation of the pathogenesis of decreasing CD4(R) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive anti-retroviral therapy. J Infect Dis 2009; 199:1648-1656.
26. R T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003; 17:2015-2023.
27. Ruiz L, van Lunzen J, Arno A, Stellbrink HJ, Schneider C, Rull M, et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999; 13:F1-F8.
28. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastro-enterol Hepatol 2009; 7:227-233.
29. Mendes-Correa MC, Widman A, Brussi ML, Guastini CF, Gia-nini RJ. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C in Brazil. AIDS Patient Care STDS 2008; 22:701-707.
30. Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copis/ml. J Infect Dis 1998; 177:235-238.
31. Gunthard H, Havlir D, Fiscus S, et al. Residual human immunodeficiency (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001; 183:1318-1327.
32. Garcia F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, et al. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. AIDS 1999; 13:2377-2388.
33. Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, Rizzardi GP, et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med 1998; 4:341-345.
34. Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006; 20:1141-1150.
35. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
36. Smith KY, Steffens CM, Truckenbrod A, Landay A, Al-Harthi L. Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretro-viral regimens. J Acquir Immune Defic Syndr 2002; 29:544-545.
37. Barreiro P, Soriano V, Casas E, Gonzalez-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or nonnucleosides. AIDS 2002; 16:245-249.
38. Kravcik S, Magill A, Sanghvi B, Ogden R, Cameron WD, Lewis R, et al. Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure. HIV Clin Trials 2001; 2:160-170.
39. Garcia F, Plana M, Mestre G, Cruceta A, Martinez E, Miro JM, et al. Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving postexposure prophylaxis. Antivir Ther 2002; 7:195-197.
40. Sloand E, Kumar PN, Chaudhuri A, Weichold FF, Young NS. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(R) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999; 94:1021-1027.
41. Weichold FF, Bryant JL, Pati S, Barabitskaya O, Gallo RC, Reitz MS. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol 1999; 2:261-269.
42. Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J, Badley AD. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001; 98:1078-1085.
43. Estaquier J, Lelievre JD, Petit F, Brunner T, Moutouh-De PL, Richman DD, et al. Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(R) T-cell death. J Virol 2002; 76:5966-5973.
44. Hunt PW, Deeks SG, Bangsberg DR, Moss A, Sinclair E, Liegler T, et al. The independent effect of drug resistance on T cell activation in HIV infection. AIDS 2006; 20:691-699.
45. Legrand FA, Abadi J, Jordan KA, Davenport MP, Deeks SG, Fennelly GJ, et al. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS 2005; 19:1575-1585.
46. Lichtner M, Mengoni F, Mastroianni CM, Sauzullo I, Rossi R, De NM, et al. HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. Apop-tosis 2006; 11:781-787.
47. Pilon AA, Lum JJ, Sanchez-Dardon J, Phenix BN, Douglas R, Badley AD. Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor. Antimicrob Agents Chemother 2002; 46:2687-2691.